Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
88.82M | 79.70M | 60.11M | 89.30M | 39.31M | 54.64M | Gross Profit |
43.91M | 38.70M | -11.68M | 26.21M | -10.68M | 6.64M | EBIT |
-20.44M | -20.58M | -70.29M | -10.53M | -31.71M | -15.14M | EBITDA |
-15.07M | -19.42M | -104.29M | -7.82M | -73.04M | -11.14M | Net Income Common Stockholders |
-9.76M | -20.99M | -108.35M | -11.38M | -74.74M | -7.77M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
17.24M | 17.52M | 26.05M | 16.31M | 27.88M | 26.03M | Total Assets |
69.59M | 66.75M | 65.60M | 125.94M | 105.92M | 161.51M | Total Debt |
6.35M | 7.00M | 4.41M | 4.92M | 4.16M | 4.59M | Net Debt |
-10.89M | -10.53M | -21.65M | -11.39M | -23.72M | -21.44M | Total Liabilities |
30.90M | 29.88M | 23.92M | 37.73M | 18.90M | 29.61M | Stockholders Equity |
38.69M | 36.87M | 41.68M | 88.21M | 87.02M | 131.90M |
Cash Flow | Free Cash Flow | ||||
-14.73M | -26.52M | -46.74M | -9.93M | -23.24M | -22.14M | Operating Cash Flow |
-14.58M | -26.33M | -46.49M | -9.37M | -22.63M | -21.92M | Investing Cash Flow |
-169.76K | -189.82K | -4.25M | -1.56M | -5.60M | -8.70M | Financing Cash Flow |
4.08M | 17.99M | 60.48M | -643.21K | 30.09M | 33.35M |
Bubs Australia Ltd. announced a favorable outcome in a legal dispute involving its subsidiary, The Infant Food Co. Pty Limited, against Alice Trading Limited and Willis Trading Limited, subsidiaries of Alpha Professional Holdings Ltd. The Australian Centre for International Commercial Arbitration awarded Bubs a total of $26.5 million for debt, breach of contract, and damages claims. This outcome strengthens Bubs’ financial position and underscores its ability to successfully navigate complex legal challenges, potentially enhancing its standing in the industry.
Bubs Australia Limited reported a positive operating cash flow for the second consecutive quarter, with a notable improvement in financial performance for Q3 FY25. The company achieved a group net revenue of $23.2 million, a 52.6% increase from the previous corresponding period, and a significant reduction in EBITDA loss. Bubs is making progress in the USA market, with strong sales growth on platforms like Amazon and in physical stores, partly due to competitors’ supply shortages. The company is also advancing its clinical trials in the USA, aiming for FDA approval later in the year, which could further enhance its market positioning.
Bubs Australia Ltd. announced a change in the indirect interest of its director, Paul Jensen, who acquired an additional 40,000 ordinary shares, bringing his total to 500,000 shares. This transaction, conducted through an on-market purchase, reflects a strategic move that could potentially impact the company’s stock market perception and investor confidence.